256 related articles for article (PubMed ID: 30003670)
21. Dapagliflozin Plus Saxagliptin Add-on Therapy Compared With Insulin in Patients With Type 2 Diabetes Poorly Controlled by Metformin With or Without Sulfonylurea Therapy: A Randomized Clinical Trial.
Vilsbøll T; Ekholm E; Johnsson E; Dronamraju N; Jabbour S; Lind M
Diabetes Care; 2019 Aug; 42(8):1464-1472. PubMed ID: 31167892
[TBL] [Abstract][Full Text] [Related]
22. Cardiovascular safety of glucose-lowering agents as add-on medication to metformin treatment in type 2 diabetes: report from the Swedish National Diabetes Register.
Ekström N; Svensson AM; Miftaraj M; Franzén S; Zethelius B; Eliasson B; Gudbjörnsdottir S
Diabetes Obes Metab; 2016 Oct; 18(10):990-8. PubMed ID: 27282621
[TBL] [Abstract][Full Text] [Related]
23. Early glycaemic control in metformin users receiving their first add-on therapy: a population-based study of 4,734 people with type 2 diabetes.
Thomsen RW; Baggesen LM; Søgaard M; Pedersen L; Nørrelund H; Buhl ES; Haase CL; Johnsen SP
Diabetologia; 2015 Oct; 58(10):2247-53. PubMed ID: 26277380
[TBL] [Abstract][Full Text] [Related]
24. Continuous glucose monitoring demonstrates low risk of clinically significant hypoglycemia associated with sulphonylurea treatment in an African type 2 diabetes population: results from the OPTIMAL observational multicenter study.
Niwaha AJ; Rodgers LR; Carr ALJ; Balungi PA; Mwebaze R; Hattersley AT; Shields BM; Nyirenda MJ; Jones AG
BMJ Open Diabetes Res Care; 2022 Apr; 10(2):. PubMed ID: 35450869
[TBL] [Abstract][Full Text] [Related]
25. Efficacy and safety of generic exenatide injection in Chinese patients with type 2 diabetes: a multicenter, randomized, controlled, non-inferiority trial.
Yang J; Xiao W; Guo L; Li Q; Zhong L; Yang J; Yang J; Gao Y; Tian Q; Hong T
Acta Diabetol; 2020 Aug; 57(8):991-1000. PubMed ID: 32206903
[TBL] [Abstract][Full Text] [Related]
26. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Lancet; 1998 Sep; 352(9131):854-65. PubMed ID: 9742977
[TBL] [Abstract][Full Text] [Related]
27. Can people with type 2 diabetes live longer than those without? A comparison of mortality in people initiated with metformin or sulphonylurea monotherapy and matched, non-diabetic controls.
Bannister CA; Holden SE; Jenkins-Jones S; Morgan CL; Halcox JP; Schernthaner G; Mukherjee J; Currie CJ
Diabetes Obes Metab; 2014 Nov; 16(11):1165-73. PubMed ID: 25041462
[TBL] [Abstract][Full Text] [Related]
28. Double-blind, randomized clinical trial assessing the efficacy and safety of early initiation of sitagliptin during metformin uptitration in the treatment of patients with type 2 diabetes: The CompoSIT-M study.
Frias JP; Zimmer Z; Lam RLH; Amorin G; Ntabadde C; Iredale C; O'Neill EA; Engel SS; Kaufman KD; Makimura H; Crutchlow MF
Diabetes Obes Metab; 2019 May; 21(5):1128-1135. PubMed ID: 30609212
[TBL] [Abstract][Full Text] [Related]
29. Efficacy and safety of basal insulin glargine 12 and 24 weeks after initiation in persons with type 2 diabetes: a pooled analysis of data from treatment arms of 15 treat-to-target randomised controlled trials.
Owens DR; Traylor L; Dain MP; Landgraf W
Diabetes Res Clin Pract; 2014 Nov; 106(2):264-74. PubMed ID: 25195151
[TBL] [Abstract][Full Text] [Related]
30. Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial.
Lavalle-González FJ; Januszewicz A; Davidson J; Tong C; Qiu R; Canovatchel W; Meininger G
Diabetologia; 2013 Dec; 56(12):2582-92. PubMed ID: 24026211
[TBL] [Abstract][Full Text] [Related]
31. Combination therapy with metformin plus sulphonylureas versus metformin plus DPP-4 inhibitors: association with major adverse cardiovascular events and all-cause mortality.
Morgan CL; Mukherjee J; Jenkins-Jones S; Holden SE; Currie CJ
Diabetes Obes Metab; 2014 Oct; 16(10):977-83. PubMed ID: 24762119
[TBL] [Abstract][Full Text] [Related]
32. Sodium-glucose co-transporter-2 inhibitors, the latest residents on the block: Impact on glycaemic control at a general practice level in England.
Heald AH; Fryer AA; Anderson SG; Livingston M; Lunt M; Davies M; Moreno GYC; Gadsby R; Young RJ; Stedman M
Diabetes Obes Metab; 2018 Jul; 20(7):1659-1669. PubMed ID: 29516618
[TBL] [Abstract][Full Text] [Related]
33. Effect of sulphonylurea treatment on glycaemic control is related to TCF7L2 genotype in patients with type 2 diabetes.
Schroner Z; Javorsky M; Tkacova R; Klimcakova L; Dobrikova M; Habalova V; Kozarova M; Zidzik J; Rudikova M; Tkac I
Diabetes Obes Metab; 2011 Jan; 13(1):89-91. PubMed ID: 21114608
[TBL] [Abstract][Full Text] [Related]
34. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group.
Turner RC; Cull CA; Frighi V; Holman RR
JAMA; 1999 Jun; 281(21):2005-12. PubMed ID: 10359389
[TBL] [Abstract][Full Text] [Related]
35. Risk of hypoglycemia following intensification of metformin treatment with insulin versus sulfonylurea.
Roumie CL; Min JY; Greevy RA; Grijalva CG; Hung AM; Liu X; Elasy T; Griffin MR
CMAJ; 2016 Apr; 188(6):E104-E112. PubMed ID: 26811361
[TBL] [Abstract][Full Text] [Related]
36. Sulphonylurea-metformin combination therapy, cardiovascular disease and all-cause mortality: the Fremantle Diabetes Study.
Sillars B; Davis WA; Hirsch IB; Davis TM
Diabetes Obes Metab; 2010 Sep; 12(9):757-65. PubMed ID: 20649627
[TBL] [Abstract][Full Text] [Related]
37. Efficacy and safety of antihyperglycaemic drug regimens added to metformin and sulphonylurea therapy in Type 2 diabetes: a network meta-analysis.
Mearns ES; Saulsberry WJ; White CM; Kohn CG; Lemieux S; Sihabout A; Salamucha I; Coleman CI
Diabet Med; 2015 Dec; 32(12):1530-40. PubMed ID: 26104021
[TBL] [Abstract][Full Text] [Related]
38. Empagliflozin as add-on to metformin plus sulphonylurea in patients with type 2 diabetes.
Haering HU; Merker L; Christiansen AV; Roux F; Salsali A; Kim G; Meinicke T; Woerle HJ; Broedl UC;
Diabetes Res Clin Pract; 2015 Oct; 110(1):82-90. PubMed ID: 26324220
[TBL] [Abstract][Full Text] [Related]
39. Mealtime 50/50 basal + prandial insulin analogue mixture with a basal insulin analogue, both plus metformin, in the achievement of target HbA1c and pre- and postprandial blood glucose levels in patients with type 2 diabetes: a multinational, 24-week, randomized, open-label, parallel-group comparison.
Robbins DC; Beisswenger PJ; Ceriello A; Goldberg RB; Moses RG; Pagkalos EM; Milicevic Z; Jones CA; Sarwat S; Tan MH
Clin Ther; 2007 Nov; 29(11):2349-64. PubMed ID: 18158076
[TBL] [Abstract][Full Text] [Related]
40. Efficacy and safety over 26 weeks of an oral treatment strategy including sitagliptin compared with an injectable treatment strategy with liraglutide in patients with type 2 diabetes mellitus inadequately controlled on metformin: a randomised clinical trial.
Charbonnel B; Steinberg H; Eymard E; Xu L; Thakkar P; Prabhu V; Davies MJ; Engel SS
Diabetologia; 2013 Jul; 56(7):1503-11. PubMed ID: 23604551
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]